{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:07:37Z","timestamp":1790262457326,"version":"4.1.0"},"reference-count":116,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Minor histocompatibility antigens (MiHA) are polymorphic peptides presented by HLA molecules on recipient cells in allogeneic hematopoietic cell transplantation (allo-HCT) and are derived from proteins with genetic variants that differ between recipient and donor. After allo-HCT, hematopoietic-restricted MiHA enable selective targeting of residual recipient-derived hematopoiesis, including malignant cells. Advances in engineering T cells with high-affinity, MiHA-specific T-cell receptors (TCR; TCR-T) are enabling clinical translation of MiHA T-cell immunotherapy. Early-phase trials of HA-1\u2013 and HA-2\u2013specific TCR-T demonstrate safety, persistence, and durable antileukemic activity in high-risk or relapsed disease. To accelerate translation, the field should expand TCR-T development to additional MiHA targets to broaden HLA and population coverage, integrate MiHA genotyping into donor selection, and devise platform trials to include patients with various MiHA\/HLA genotypes and to efficiently test combination therapies. MiHA-directed TCR-T represents a genetically precise, potentially routine HCT adjunct that promises to fortify graft-versus-leukemia effects and improve relapse-free survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018015","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:54:17Z","timestamp":1783032857000},"page":"6064-6078","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Minor histocompatibility antigen TCR-T"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3799","authenticated-orcid":false,"given":"Elizabeth F.","family":"Krakow","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7018-8702","authenticated-orcid":false,"given":"Marie","family":"Bleakley","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Department of Pediatrics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"5","key":"2026092410261284900_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc1365","article-title":"Molecules and mechanisms of the graft-versus-leukaemia effect","volume":"4","author":"Bleakley","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2026092410261284900_bib2","doi-asserted-by":"crossref","first-page":"e134939","DOI":"10.1172\/jci.insight.134939","article-title":"T cell optimization for graft-versus-leukemia responses","volume":"5","author":"Biernacki","year":"2020","journal-title":"JCI Insight"},{"key":"2026092410261284900_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fimmu.2016.00100","article-title":"Autosomal minor histocompatibility antigens: how genetic variants create diversity in immune targets","volume":"7","author":"Griffioen","year":"2016","journal-title":"Front Immunol"},{"issue":"10","key":"2026092410261284900_bib4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20030044","article-title":"A human minor histocompatibility antigen resulting from differential expression due to a gene deletion","volume":"197","author":"Murata","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"2026092410261284900_bib5","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1172\/JCI24832","article-title":"A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia","volume":"115","author":"de Rijke","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"2026092410261284900_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2003-01-0260","article-title":"The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein","volume":"102","author":"Spierings","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2026092410261284900_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.193.2.195","article-title":"The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing","volume":"193","author":"Brickner","year":"2001","journal-title":"J Exp Med"},{"issue":"2","key":"2026092410261284900_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00251-011-0590-0","article-title":"TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition","volume":"64","author":"D'Orsogna","year":"2012","journal-title":"Immunogenetics"},{"issue":"8","key":"2026092410261284900_bib9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"issue":"26","key":"2026092410261284900_bib10","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood.2023019962","article-title":"Tricking the trickster: precision medicine approaches to counteract leukemia immune escape after transplant","volume":"143","author":"Tameni","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026092410261284900_bib11","doi-asserted-by":"crossref","first-page":"e007490","DOI":"10.1136\/jitc-2023-007490","article-title":"Discovery of U2AF1 neoantigens in myeloid neoplasms","volume":"11","author":"Biernacki","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2026092410261284900_bib12","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/2326-6066.CIR-24-0091","article-title":"SF3B1K700E neoantigen is a CD8+ T-cell target shared across human myeloid neoplasms","volume":"13","author":"Biernacki","year":"2025","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2026092410261284900_bib13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s43018-023-00642-8","article-title":"A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo","volume":"4","author":"Giannakopoulou","year":"2023","journal-title":"Nat Cancer"},{"issue":"8","key":"2026092410261284900_bib14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","article-title":"Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors","volume":"10","author":"Kim","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"22","key":"2026092410261284900_bib15","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"2026092410261284900_bib16","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1182\/blood.2023021979","article-title":"Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia","volume":"143","author":"Leung","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026092410261284900_bib17","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/biomedicines12051086","article-title":"Hotspot DNA methyltransferase 3A (DNMT3A) and isocitrate dehydrogenase 1 and 2 (IDH1\/2) mutations in acute myeloid leukemia and their relevance as targets for immunotherapy","volume":"12","author":"Struckman","year":"2024","journal-title":"Biomedicines"},{"issue":"21","key":"2026092410261284900_bib18","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.3390\/cancers13215390","article-title":"An HLA-A\u221711:01-binding neoantigen from mutated NPM1 as target for TCR gene therapy in AML","volume":"13","author":"van der Lee","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026092410261284900_bib19","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"van der Lee","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"2026092410261284900_bib20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41408-025-01370-1","article-title":"Identification of specific T-cell response and T-cell receptor targeting shared neoantigen for acute myeloid leukemia","volume":"15","author":"Zhou","year":"2025","journal-title":"Blood Cancer J"},{"issue":"13","key":"2026092410261284900_bib21","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.cell.2025.03.047","article-title":"Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias","volume":"188","author":"Kim","year":"2025","journal-title":"Cell"},{"issue":"2","key":"2026092410261284900_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41375-025-02817-x","article-title":"A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia","volume":"40","author":"Struckman","year":"2026","journal-title":"Leukemia"},{"issue":"10","key":"2026092410261284900_bib23","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1172\/JCI137723","article-title":"CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia","volume":"130","author":"Biernacki","year":"2020","journal-title":"J Clin Invest"},{"issue":"10","key":"2026092410261284900_bib24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41375-025-02710-7","article-title":"Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias","volume":"39","author":"Tirtakusuma","year":"2025","journal-title":"Leukemia"},{"key":"2026092410261284900_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fimmu.2020.00121","article-title":"Neoantigens in hematologic malignancies","volume":"11","author":"Biernacki","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"2026092410261284900_bib26","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2024014105","article-title":"Current developments in T-cell receptor therapy for acute myeloid leukemia","volume":"9","author":"Gore","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026092410261284900_bib27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/89907","article-title":"Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease","volume":"7","author":"Fontaine","year":"2001","journal-title":"Nat Med"},{"issue":"1","key":"2026092410261284900_bib28","doi-asserted-by":"crossref","first-page":"e4116","DOI":"10.1371\/journal.pone.0004116","article-title":"Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice","volume":"4","author":"Meunier","year":"2009","journal-title":"PLoS One"},{"issue":"7","key":"2026092410261284900_bib29","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1172\/JCI39165","article-title":"Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice","volume":"120","author":"Asakura","year":"2010","journal-title":"J Clin Invest"},{"issue":"4","key":"2026092410261284900_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1365-2141.2002.03536.x","article-title":"Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion","volume":"117","author":"Kircher","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"2026092410261284900_bib31","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1073\/pnas.0530192100","article-title":"Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia","volume":"100","author":"Marijt","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026092410261284900_bib32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00002371-200403000-00009","article-title":"Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion","volume":"27","author":"Kircher","year":"2004","journal-title":"J Immunother"},{"issue":"4","key":"2026092410261284900_bib33","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.leu.2403297","article-title":"Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells","volume":"18","author":"Kloosterboer","year":"2004","journal-title":"Leukemia"},{"issue":"18","key":"2026092410261284900_bib34","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood.2023022343","article-title":"Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens","volume":"143","author":"Fuchs","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026092410261284900_bib35","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41587-024-02348-3","article-title":"Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation","volume":"43","author":"Cieri","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"9","key":"2026092410261284900_bib36","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/bloodadvances.2022008863","article-title":"Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT","volume":"7","author":"Olsen","year":"2023","journal-title":"Blood Adv"},{"key":"2026092410261284900_bib37","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3389\/fimmu.2018.01819","article-title":"In silico analysis of the minor histocompatibility antigen landscape based on the 1000 Genomes Project","volume":"9","author":"Bykova","year":"2018","journal-title":"Front Immunol"},{"issue":"5216","key":"2026092410261284900_bib72","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1126\/science.7539551","article-title":"Identification of a graft versus host disease-associated human minor histocompatibility antigen","volume":"268","author":"den Haan","year":"1995","journal-title":"Science"},{"issue":"2","key":"2026092410261284900_bib112","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1172\/JCI86175","article-title":"Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response","volume":"127","author":"van Bergen","year":"2017","journal-title":"J Clin Invest"},{"issue":"11","key":"2026092410261284900_bib113","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1084\/jem.20021925","article-title":"Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens","volume":"197","author":"Akatsuka","year":"2003","journal-title":"J Exp Med"},{"issue":"6","key":"2026092410261284900_bib114","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2007-10-118950","article-title":"Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA","volume":"111","author":"Kawase","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2026092410261284900_bib115","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-10-1832","article-title":"High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning","volume":"70","author":"Van Bergen","year":"2010","journal-title":"Cancer Res"},{"issue":"5353","key":"2026092410261284900_bib48","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1126\/science.279.5353.1054","article-title":"The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism","volume":"279","author":"den Haan","year":"1998","journal-title":"Science"},{"issue":"8","key":"2026092410261284900_bib38","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2026092410261284900_bib39","doi-asserted-by":"crossref","first-page":"e0119595","DOI":"10.1371\/journal.pone.0119595","article-title":"Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission","volume":"10","author":"van der Torren","year":"2015","journal-title":"PLoS One"},{"key":"2026092410261284900_bib40","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3389\/fimmu.2018.03016","article-title":"CD4 donor lymphocyte infusion can cause conversion of chimerism without GVHD by inducing immune responses targeting minor histocompatibility antigens in HLA class II","volume":"9","author":"van Balen","year":"2018","journal-title":"Front Immunol"},{"issue":"19","key":"2026092410261284900_bib41","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1182\/blood-2009-10-248997","article-title":"Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens","volume":"115","author":"Warren","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2026092410261284900_bib42","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3324\/haematol.2011.053371","article-title":"Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study","volume":"97","author":"Meij","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2026092410261284900_bib43","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.bbmt.2009.03.018","article-title":"Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants","volume":"15","author":"Spellman","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2026092410261284900_bib44","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.bbmt.2013.06.001","article-title":"Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation","volume":"19","author":"Spierings","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2026092410261284900_bib45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbmt.2012.09.008","article-title":"Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation","volume":"19","author":"Hobo","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2026092410261284900_bib46","doi-asserted-by":"crossref","first-page":"101555","DOI":"10.1016\/j.beha.2024.101555","article-title":"Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation","volume":"37","author":"Fuchs","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"2026092410261284900_bib47","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2026092410261284900_bib49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fped.2020.00284","article-title":"Minor histocompatibility antigen-specific T cells","volume":"8","author":"Summers","year":"2020","journal-title":"Front Pediatr"},{"issue":"10","key":"2026092410261284900_bib50","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1073\/pnas.0900411106","article-title":"Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition","volume":"106","author":"Nicholls","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2026092410261284900_bib51","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.4049\/jimmunol.0803911","article-title":"Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele","volume":"182","author":"Spierings","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"2026092410261284900_bib52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.bmt.1705689","article-title":"The HLA-A\u22170201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A\u22170206","volume":"40","author":"Torikai","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2026092410261284900_bib53","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nm0402-410","article-title":"In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens","volume":"8","author":"Dickinson","year":"2002","journal-title":"Nat Med"},{"issue":"5","key":"2026092410261284900_bib54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.thj.6200318","article-title":"Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies","volume":"4","author":"Wilke","year":"2003","journal-title":"Hematol J"},{"issue":"12","key":"2026092410261284900_bib55","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/2159-8290.CD-25-0299","article-title":"Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies","volume":"15","author":"Zhang","year":"2025","journal-title":"Cancer Discov"},{"issue":"5","key":"2026092410261284900_bib56","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.4049\/jimmunol.149.5.1788","article-title":"Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens","volume":"149","author":"de Bueger","year":"1992","journal-title":"J Immunol"},{"issue":"1","key":"2026092410261284900_bib57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood-2017-07-791608","article-title":"Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse","volume":"131","author":"Dossa","year":"2018","journal-title":"Blood"},{"key":"2026092410261284900_bib58","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3389\/fimmu.2020.01804","article-title":"HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: a phase 1 clinical study","volume":"11","author":"van Balen","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"2026092410261284900_bib59","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.jtct.2025.01.096","article-title":"TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning (RIC): preliminary results from the phase 1 ALLOHA Trial (NCT05473910)","volume":"31","author":"Malki","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2026092410261284900_bib60","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/j.jtct.2025.12.206","article-title":"TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT (allo-HCT) with reduced intensity conditioning (RIC): updated results from the phase 1 ALLOHA Trial","volume":"32","author":"Malki","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2026092410261284900_bib61","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.2024024105","article-title":"HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026092410261284900_bib62","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2014.01.032","article-title":"Engineering human peripheral blood stem cell grafts that are depleted of naive T cells and retain functional pathogen-specific memory T cells","volume":"20","author":"Bleakley","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2026092410261284900_bib63","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts","volume":"125","author":"Bleakley","year":"2015","journal-title":"J Clin Invest"},{"issue":"11","key":"2026092410261284900_bib64","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease","volume":"40","author":"Bleakley","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026092410261284900_bib65","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Invest"},{"issue":"1","key":"2026092410261284900_bib66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.immuni.2014.05.018","article-title":"Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells","volume":"41","author":"Graef","year":"2014","journal-title":"Immunity"},{"issue":"9","key":"2026092410261284900_bib67","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e318270dec7","article-title":"Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale","volume":"35","author":"Wang","year":"2012","journal-title":"J Immunother"},{"issue":"18","key":"2026092410261284900_bib68","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"2026092410261284900_bib69","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbmt.2007.04.005","article-title":"Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation","volume":"13","author":"Tey","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2026092410261284900_bib70","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2026092410261284900_bib71","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.4049\/jimmunol.167.6.3223","article-title":"The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein","volume":"167","author":"Pierce","year":"2001","journal-title":"J Immunol"},{"issue":"Supplement 1","key":"2026092410261284900_bib73","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2025-2391","article-title":"TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial","volume":"146","author":"Al Malki","year":"2025","journal-title":"Blood"},{"key":"2026092410261284900_bib74","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3389\/fimmu.2020.00381","article-title":"Discovery and differential processing of HLA class II-restricted minor histocompatibility antigen LB-PIP4K2A-1S and its allelic variant by asparagine endopeptidase","volume":"11","author":"Kremer","year":"2020","journal-title":"Front Immunol"},{"issue":"17","key":"2026092410261284900_bib75","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2009-03-208017","article-title":"Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity","volume":"114","author":"Stumpf","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2026092410261284900_bib76","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"2026092410261284900_bib77","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1182\/blood-2009-12-260539","article-title":"Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells","volume":"115","author":"Bleakley","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2026092410261284900_bib78","doi-asserted-by":"crossref","first-page":"e23217","DOI":"10.1371\/journal.pone.0023217","article-title":"Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data","volume":"6","author":"Armistead","year":"2011","journal-title":"PLoS One"},{"key":"2026092410261284900_bib79","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/ncomms4600","article-title":"Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides","volume":"5","author":"Granados","year":"2014","journal-title":"Nat Commun"},{"issue":"6","key":"2026092410261284900_bib80","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2016.22","article-title":"Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers","volume":"30","author":"Granados","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2026092410261284900_bib81","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7150\/thno.104594","article-title":"Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"issue":"12","key":"2026092410261284900_bib82","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41568-025-00857-0","article-title":"Targeting the roots of myeloid malignancies with T cell receptors","volume":"25","author":"Foldvari","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2026092410261284900_bib83","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2019.07.009","article-title":"T-Scan: a genome-wide method for the systematic discovery of T cell epitopes","volume":"178","author":"Kula","year":"2019","journal-title":"Cell"},{"issue":"4","key":"2026092410261284900_bib84","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/bloodadvances.2025017680","article-title":"High throughput cloning reveals diverse properties of T cell receptors targeting minor histocompatibility antigens","volume":"10","author":"Ito","year":"2026","journal-title":"Blood Adv"},{"issue":"7","key":"2026092410261284900_bib85","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"22","key":"2026092410261284900_bib86","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2017-04-777052","article-title":"A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia","volume":"130","author":"Oda","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2026092410261284900_bib87","doi-asserted-by":"crossref","first-page":"e20191166","DOI":"10.1084\/jem.20191166","article-title":"A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy","volume":"217","author":"Oda","year":"2020","journal-title":"J Exp Med"},{"issue":"26","key":"2026092410261284900_bib88","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.2025029532","article-title":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"issue":"8047","key":"2026092410261284900_bib89","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"9","key":"2026092410261284900_bib90","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"key":"2026092410261284900_bib91","doi-asserted-by":"crossref","first-page":"1460266","DOI":"10.3389\/fimmu.2024.1460266","article-title":"Targeting TGFbeta with chimeric switch receptor and secreted trap to improve T cells anti-tumor activity","volume":"15","author":"Matikhina","year":"2024","journal-title":"Front Immunol"},{"issue":"39","key":"2026092410261284900_bib92","doi-asserted-by":"crossref","first-page":"e2516951122","DOI":"10.1073\/pnas.2516951122","article-title":"A TGF-betaR\/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy","volume":"122","author":"Su","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026092410261284900_bib93","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4049\/jimmunol.2001357","article-title":"Engineering cancer antigen-specific T cells to overcome the immunosuppressive effects of TGF-beta","volume":"208","author":"Silk","year":"2022","journal-title":"J Immunol"},{"issue":"8016","key":"2026092410261284900_bib94","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"issue":"5","key":"2026092410261284900_bib95","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026092410261284900_bib96","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1158\/1535-7163.MCT-21-0348","article-title":"Efficacy of Rac and Cdc42 inhibitor MBQ-167 in triple-negative breast cancer","volume":"20","author":"Cruz-Collazo","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"suppl 1","key":"2026092410261284900_bib97","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2024-198954","article-title":"Systematic evaluation of GAPs and Gefs identifies ARHGAP45 as a targetable leukemia-specific dependency","volume":"144","author":"Zhang","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026092410261284900_bib98","doi-asserted-by":"crossref","first-page":"e010073","DOI":"10.1136\/jitc-2024-010073","article-title":"BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer","volume":"13","author":"Zhang","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"14","key":"2026092410261284900_bib99","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1042\/CS20210571","article-title":"A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis","volume":"135","author":"Zhang","year":"2021","journal-title":"Clin Sci"},{"issue":"8","key":"2026092410261284900_bib100","doi-asserted-by":"crossref","first-page":"e22827","DOI":"10.1002\/jbt.22827","article-title":"Azilsartan prevented AGE-induced inflammatory response and degradation of aggrecan in human chondrocytes through inhibition of Sox4","volume":"35","author":"Lei","year":"2021","journal-title":"J Biochem Mol Toxicol"},{"issue":"76","key":"2026092410261284900_bib101","doi-asserted-by":"crossref","first-page":"eabo3420","DOI":"10.1126\/sciimmunol.abo3420","article-title":"Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity","volume":"7","author":"Minnie","year":"2022","journal-title":"Sci Immunol"},{"issue":"23","key":"2026092410261284900_bib102","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1158\/1078-0432.CCR-23-0917","article-title":"The New NCI Precision Medicine Trials","volume":"29","author":"Harris","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026092410261284900_bib103","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jmoldx.2025.05.001","article-title":"Analytical performance of the NCI-myeloMATCH assay: a rapid turnaround genomic profiling assay for myeloid disorders","volume":"27","author":"Yeung","year":"2025","journal-title":"J Mol Diagn"},{"key":"2026092410261284900_bib104","first-page":"JCO2600113","article-title":"Donor selection and human leukocyte antigen loss leukemia relapse after hematopoietic cell transplantation","volume":"25","author":"Fleischhauer","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026092410261284900_bib105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/sim.9242","article-title":"A Bayesian phase I\/II platform design for co-developing drug combination therapies for multiple indications","volume":"41","author":"Mu","year":"2022","journal-title":"Stat Med"},{"issue":"10\u201312","key":"2026092410261284900_bib106","doi-asserted-by":"crossref","first-page":"e70107","DOI":"10.1002\/sim.70107","article-title":"COMIC: a Bayesian dose optimization design for drug combination in multiple indications with application to CAR-T therapies","volume":"44","author":"Chen","year":"2025","journal-title":"Stat Med"},{"issue":"3","key":"2026092410261284900_bib107","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/17407745231220661","article-title":"Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies","volume":"21","author":"Zang","year":"2024","journal-title":"Clin Trials"},{"issue":"4","key":"2026092410261284900_bib108","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/1078-0432.CCR-17-1355","article-title":"Sequential, multiple assignment, randomized trial designs in immuno-oncology research","volume":"24","author":"Kidwell","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026092410261284900_bib109","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fimmu.2018.00331","article-title":"Tissue damage caused by myeloablative, but not non-myeloablative, conditioning before allogeneic stem cell transplantation results in dermal macrophage recruitment without active T-cell interaction","volume":"9","author":"van Balen","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"2026092410261284900_bib110","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2026092410261284900_bib111","doi-asserted-by":"crossref","first-page":"E220","DOI":"10.1002\/ajh.26540","article-title":"Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation","volume":"97","author":"Krakow","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"2026092410261284900_bib116","doi-asserted-by":"crossref","first-page":"e0155165","DOI":"10.1371\/journal.pone.0155165","article-title":"Microarray gene expression analysis to evaluate cell type specific expression of targets relevant for immunotherapy of hematological malignancies","volume":"11","author":"Pont","year":"2016","journal-title":"PLoS One"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6064\/2587725\/blooda_adv-2025-018015-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6064\/2587725\/blooda_adv-2025-018015-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:31:48Z","timestamp":1790260308000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6064\/569498\/Minor-histocompatibility-antigen-TCR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":116,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018015","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,9]]}}}